Lessons from the novel D2 dopamine receptor, β2-adrenoceptor agonist, Viozan™: Chronic obstructive pulmonary disease and drug development implications

4Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

The development of novel drugs for the treatment of chronic obstructive pulmonary disease (COPD) poses significant challenges.The mechanisms through which the chronic symptoms of COPD arise are poorly understood, making identification of potential therapeutic targets and in vivo evaluation of potential therapies extremely difficult. Despite these challenges, a unique approach of combined D2 dopamine, β2-adrenoceptor agonism was identified as a valid potential target for the treatment of key COPD symptoms, the therapeutic potential of which was investigated in a series of preclinical evaluations. Subsequent clinical assessment has amassed a wealth of data from over 4000 patients, providing valuable insights into COPD, clinical trial design and the value of patient self-assessment tools. © 2003 Elsevier Science Ltd.

Cite

CITATION STYLE

APA

Calverley, P., Keating, E. T., Goldman, M., & Casty, F. (2003, January 1). Lessons from the novel D2 dopamine receptor, β2-adrenoceptor agonist, ViozanTM: Chronic obstructive pulmonary disease and drug development implications. Respiratory Medicine. W.B. Saunders Ltd. https://doi.org/10.1016/S0954-6111(03)80017-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free